ArticleOpen veterinary journal2025
Therapeutic potential of branched-chain amino acids against carbon tetrachloride-induced cardiopulmonary injuries in Wistar rats.
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Background: Carbon tetrachloride (CCl4) is a xenobiotic hepatotoxic agent that causes pathophysiological disorders in tissues and the liver. CCl4-induced cardiopulmonary toxicity is attributed to free radical-induced dyslipidemia and oxidative damage. Branched-chain amino acids (BCAAs) stimulate systemic defense against oxidative stress, which is probably caused by CCl4, through an improvement in the antioxidant system. Aim: This study aimed to explore the therapeutic benefits of BCAAs against CCl4-induced cardiopulmonary pathologies. Methods: A total of 28 inclusive Wistar rats stand under control was standard; group 2 comprised CCl4-received rats, whereas groups 3 and 4 comprised CCl4-rats supplemented with two varying levels of BCAAs. Results: Biochemical findings indicated that CCl4 provoked a rise in glucose and cholesterol levels compared with the control. The oxidative profile suggested increased malondialdehyde level and decreased superoxide dismutase activity in the CCl4-intoxicated heart. Supplemented BCAAs downregulated dyslipidemia and restored atrial changes in antioxidant components to be close to normal. Histopathological investigations using hematoxylin-eosin stain revealed damage to the inflamed heart-lung parenchyma of CCl4-intoxicated rats. An increase in fibrosis expression was detectable, simultaneously with a deprivation of protein content in cardiopulmonary sections, as shown by Masson trichrome and bromophenol blue techniques. Co-treated BCAAs intensified cardiopulmonary integrity, inducing scarce histological fibrosis with abundant protein. Accordingly, BCAA supplementation in CCl4-treated rats mitigated complications by reducing serum toxicity, enhancing antioxidant capacity, restoring protein expression, and improving organ health. Conclusion: The findings support the protective role of BCAAs with antioxidant benefits against CCl4-induced damage, suggesting their potential as a therapeutic agent for cardiopulmonary pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.